Geneva Capital Management LLC Has $52.14 Million Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Geneva Capital Management LLC trimmed its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 201,838 shares of the biotechnology company’s stock after selling 1,281 shares during the period. Geneva Capital Management LLC’s holdings in Axon Enterprise were worth $52,141,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Cambridge Investment Research Advisors Inc. boosted its position in Axon Enterprise by 8.9% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 7,716 shares of the biotechnology company’s stock valued at $1,535,000 after buying an additional 630 shares during the last quarter. Stratos Wealth Partners LTD. boosted its holdings in Axon Enterprise by 18.3% in the third quarter. Stratos Wealth Partners LTD. now owns 4,960 shares of the biotechnology company’s stock valued at $987,000 after acquiring an additional 766 shares during the last quarter. Bank of New York Mellon Corp increased its position in Axon Enterprise by 28.3% in the third quarter. Bank of New York Mellon Corp now owns 726,400 shares of the biotechnology company’s stock worth $144,546,000 after purchasing an additional 160,359 shares during the period. Mackenzie Financial Corp raised its holdings in Axon Enterprise by 2.3% during the 3rd quarter. Mackenzie Financial Corp now owns 6,292 shares of the biotechnology company’s stock worth $1,208,000 after purchasing an additional 141 shares during the last quarter. Finally, Advisor Partners II LLC lifted its position in Axon Enterprise by 3.5% during the 3rd quarter. Advisor Partners II LLC now owns 3,407 shares of the biotechnology company’s stock valued at $678,000 after purchasing an additional 115 shares during the period. 79.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Wednesday, April 24th. Argus began coverage on Axon Enterprise in a research note on Wednesday, March 13th. They issued a “buy” rating and a $380.00 price target on the stock. TheStreet cut Axon Enterprise from a “b” rating to a “c+” rating in a research note on Tuesday, February 27th. StockNews.com lowered Axon Enterprise from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Finally, JPMorgan Chase & Co. boosted their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research report on Thursday, April 11th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and an average price target of $333.08.

Axon Enterprise Stock Down 0.9 %

Shares of AXON traded down $2.77 on Thursday, hitting $309.09. The company’s stock had a trading volume of 699,189 shares, compared to its average volume of 479,508. The company has a quick ratio of 2.66, a current ratio of 3.00 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $23.32 billion, a price-to-earnings ratio of 91.19 and a beta of 0.91. The firm’s fifty day moving average price is $310.82 and its 200-day moving average price is $267.44. Axon Enterprise, Inc. has a fifty-two week low of $175.37 and a fifty-two week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Monday, May 6th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.20. The company had revenue of $460.74 million during the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. The firm’s revenue was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.51 earnings per share. On average, equities research analysts expect that Axon Enterprise, Inc. will post 2.44 EPS for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.